Long-term survival of male patients with invasive breast cancer in Southern Taiwan

This study aimed to assess the survival rates of male patients diagnosed with invasive breast cancer. A comprehensive review of medical records of 28 male breast cancer patients in Southern Taiwan from 2006 to 2017 was conducted, and Kaplan-Meier analysis was computed to estimate survival probabilities. Among the 28 patients, 22 (78.6%) were diagnosed with left-sided breast cancer, while 6 (21.4%) had right-sided breast cancer. Within the subgroup of 22 patients with left-sided breast cancer, 5 individuals succumbed to the disease during the ten-year observation period. Further analysis revealed that the estimated survival rates at both the 5-year and 10-year intervals were 57.1%, and the median survival duration was 87.7 months, with a 95% confidence interval spanning from 69.5 to 105.8 months. Univariate Cox regression analysis identified stage (p = 0.034), pathological N (p = 0.0001), and distant metastasis (p = 0.007) as significant variables associated with patient survival, but none of these were independent variables on multivariate Cox regression analysis. Taken together, despite the relatively limited sample size of this study, which reflects the rarity of male breast cancer cases, our findings underscore the critical importance of early diagnosis and timely treatment in preventing disease recurrence and improving overall survival rates in male breast cancer patients.

Male breast cancer; Survival analyses; Follow-up study

[1] Lee E, Jung S, Lim MC, Lim J, Kang H, Lee S, et al. Comparing the characteristics and outcomes of male and female breast cancer patients in Korea: Korea central cancer registry. Cancer Research and Treatment. 2020; 52: 739–746.

[2] DeSantis CE, Ma J, Gaudet MM, Newman LA, Miller KD, Goding Sauer A, et al. Breast cancer statistics, 2019. CA: A Cancer Journal for Clinicians. 2019; 69: 438–451.

[3] Liu N, Yang D, Wu Y, Xue W, Li D, Zhang J, et al. Burden, trends, and risk factors for breast cancer in China from 1990 to 2019 and its predictions until 2034: an up-to-date overview and comparison with those in Japan and South Korea. BMC Cancer. 2022; 22: 826.

[4] Giordano SH. Breast cancer in men. The New England Journal of Medicine. 2018; 378: 2311–2320.

[5] Garreffa E, Arora D. Breast cancer in the elderly, in men and during pregnancy. Surgery. 2022; 40: 139–146.

[6] Cardoso F, Bartlett JMS, Slaets L, van Deurzen CHM, van Leeuwen-Stok E, Porter P, et al. Characterization of male breast cancer: results of the EORTC 10085/TBCRC/BIG/NABCG international male breast cancer program. Annals of Oncology. 2018; 29: 405–417.

[7] Abdelwahab Yousef AJ. Male breast cancer: epidemiology and risk factors. Seminars in Oncology. 2017; 44: 267–272.

[8] Gucalp A, Traina TA, Eisner JR, Parker JS, Selitsky SR, Park BH, et al. Male breast cancer: a disease distinct from female breast cancer. Breast Cancer Research and Treatment. 2019; 173: 37–48.

[9] Pensabene M, Von Arx C, De Laurentiis M. Male breast cancer: from molecular genetics to clinical management. Cancers. 2022; 14: 2006.

[10] Evans DGR, Bulman M, Young K, Howard E, Bayliss S, Wallace A, et al. BRCA1/2 mutation analysis in male breast cancer families from North West England. Familial Cancer. 2008; 7: 113–117.

[11] McFarland BJ, Luo A, Wang X. Male breast cancer: report of two cases with bloody nipple discharge. Radiology Case Reports. 2023; 18: 3323–3330.

[12] Newman LA. Breast cancer screening in low and middle-income countries. Best Practice & Research Clinical Obstetrics & Gynaecology. 2022; 83: 15–23.

[13] Avcu S, Izmirli M, Nursun Ozcan H, Sengül I, Lemmerling M. Aryepiglottic fold and subcutaneous metastases from breast carcinoma. JBR-BTR. 2009; 92: 283–284.

[14] Institute NC. Surveillance, epidemiology, and end results program. SEER Cancer Statistics Review. 1975–2011. 2011. Available at: https://seer.cancer.gov/archive/csr/1975_2011/ (Accessed: 27 August 2023).

[15] Serdy KM, Leone JP, Dabbs DJ, Bhargava R. Male breast cancer: a single-institution clinicopathologic and immunohistochemical study. American Journal of Clinical Pathology. 2017; 147: 110–119.

[16] Liu F, Lin H, Kuo C, See L, Chiou M, Yu H. Epidemiology and survival outcome of breast cancer in a nationwide study. Oncotarget. 2017; 8: 16939–16950.

[17] Makdissi FBA, Santos SS, Bitencourt A, Campos FAB. An introduction to male breast cancer for urologists: epidemiology, diagnosis, principles of treatment, and special situations. International Brazilian Journal of Urology. 2022; 48: 760–770.

[18] Zheng G, Leone JP. Male breast cancer: an updated review of epidemiology, clinicopathology, and treatment. Journal of Oncology. 2022; 2022: 1734049.

[19] Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A. AJCC cancer staging manual. 7th edn. Springer: New York. 2010.

[20] Wu SC, Chiang MC, Lee YG, Wang MW, Li CF, Tung TH, et al. Long-term survival and prognostic implications of patients with invasive breast cancer in southern Taiwan. Medicine. 2020; 99: e19122.

[21] Ferzoco RM, Ruddy KJ. The epidemiology of male breast cancer. Current Oncology Reports. 2016; 18: 1.

[22] Gnerlich JL, Deshpande AD, Jeffe DB, Seelam S, Kimbuende E, Margenthaler JA. Poorer survival outcomes for male breast cancer compared with female breast cancer may be attributable to in-stage migration. Annals of Surgical Oncology. 2011; 18: 1837–1844.

[23] Fox S, Speirs V, Shaaban AM. Male breast cancer: an update. Virchows Archiv. 2022; 480: 85–93.

[24] Yao N, Shi W, Liu T, Siyin ST, Wang W, Duan N, et al. Clinicopathologic characteristics and prognosis for male breast cancer compared to female breast cancer. Scientific Reports. 2022; 12: 220.

[25] Abdou Y, Gupta M, Asaoka M, Attwood K, Mateusz O, Gandhi S, et al. Left sided breast cancer is associated with aggressive biology and worse outcomes than right sided breast cancer. Scientific Reports. 2022; 12: 13377.

[26] Konduri S, Singh M, Bobustuc G, Rovin R, Kassam A. Epidemiology of male breast cancer. The Breast. 2020; 54: 8–14.

[27] Kim DY, Youn J, Park M, Lee S, Choi S, Ryu K, et al. Cardiovascular outcome of breast cancer patients with concomitant radiotherapy and chemotherapy: a 10-year multicenter cohort study. Journal of Cardiology. 2019; 74: 175–181.

[28] Cheng Y, Nie X, Ji C, Lin X, Liu L, Chen X, et al. Long-term cardiovascular risk after radiotherapy in women with breast cancer. Journal of the American Heart Association. 2017; 6: e005633.

[29] Yang H, Bhoo-Pathy N, Brand JS, Hedayati E, Grassmann F, Zeng E, et al. Risk of heart disease following treatment for breast cancer—results from a population-based cohort study. eLife. 2022; 11: e71562.

[30] Prokop J, Maršálek P, Sengul I, Pelikán A, Janoutová J, Horyl P, et al. Evaluation of breast stiffness pathology based on breast compression during mammography: proposal for novel breast stiffness scale classification. Clinics. 2022; 77: 100100.

[31] Matheka M, Wasike R. Characteristics and treatment of breast cancer in men: a 12-year single-institution review. Annals of African Surgery. 2023; 20: 82–86.

[32] Soares Junior JM, Kesicioglu T, Sengul D, Sengul I. Of sight, and insight into melatonin’s role in breast cancer? Revista da Associação Médica Brasileira. 2023; 69: e697EDIT.